keyword
MENU ▼
Read by QxMD icon Read
search

neoadjuvant breast cancer therapy

keyword
https://www.readbyqxmd.com/read/29345443/suv-calculation-in-breast-cancer-which-normalization-should-be-applied-when-using-18f-fdg-pet
#1
Olivier Humbert, Jean-Marc Riedinger, David Chardin, Isabelle Desmoulins, François Brunotte, Alexandre Cochet
BACKGROUND: When using 18F-FDG PET, glucose metabolism quantification is affected by various factors. We aimed to investigate the benefit of different SUV normalizations to improve the accuracy of 18F-FDG uptake to predict breast cancer aggressiveness and response to treatment. METHODS: Two hundred fifty-two women with locally advanced breast cancer treated with neoadjuvant chemotherapy (NAC) were included. Women underwent 18F-FDG PET before and after the first course of NAC...
January 17, 2018: Quarterly Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29344722/benefit-of-the-addition-of-hormone-therapy-to-neoadjuvant-anthracycline-based-chemotherapy-for-breast-cancer-comparison-of-predicted-and-observed-pcr
#2
Daniele Generali, Silvia Paola Corona, Lajos Pusztai, Roman Rouzier, Giovanni Allevi, Sergio Aguggini, Manuela Milani, Carla Strina, Albane Frati
INTRODUCTION: Neoadjuvant hormonal therapy is generally considered a valid option for hormone receptor positive breast cancer (BC) patients who are unfit for chemotherapy or surgery. AIMS: Whilst numerous studies analyzed efficacy of neoadjuvant chemotherapy (CT) or endocrine therapy (HT) alone in hormone receptor positive patients, there is a lack of research looking at the usefulness of a preoperative combinatorial approach of CT and HT in this patient subgroup...
January 17, 2018: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29344106/overall-survival-and-progression-free-survival-with-endocrine-therapy-for-hormone-receptor-positive-her2-negative-advanced-breast-cancer-review
#3
REVIEW
Tomás Reinert, Carlos H Barrios
We reviewed randomized phase II/III trials comparing first- or second-line endocrine therapy as monotherapy or in combination with targeted therapies for treatment of postmenopausal patients with hormone receptor-positive advanced breast cancer. First-line was defined as treatment for endocrine therapy-naïve advanced breast cancer or advanced disease treated with endocrine therapy in the adjuvant/neoadjuvant setting. Second-line was defined as endocrine therapy for advanced breast cancer following disease progression on endocrine therapy for advanced disease...
November 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29334915/monitoring-the-responsiveness-of-t-and-antigen-presenting-cell-compartments-in-breast-cancer-patients-is-useful-to-predict-clinical-tumor-response-to-neoadjuvant-chemotherapy
#4
David A Bernal-Estévez, Oscar García, Ramiro Sánchez, Carlos A Parra-López
BACKGROUND: Vaccination of mice with tumors treated with Doxorubicin promotes a T cell immunity that relies on dendritic cell (DC) activation and is responsible for tumor control in vaccinated animals. Despite Doxorubicin in combination with Cyclophosphamide (A/C) is widely used to treat breast cancer patients, the stimulating effect of A/C on T and APC compartments and its correlation with patient's clinical response remains to be proved. METHODS: In this prospective study, we designed an in vitro system to monitor various immunological readouts in PBMCs obtained from a total of 17 breast cancer patients before, and after neoadjuvant anti-tumor therapy with A/C...
January 15, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29332418/the-role-of-pet-and-mri-in-evaluating-the-feasibility-of-skin-sparing-mastectomy-following-neoadjuvant-therapy
#5
Fatma Umit Malya, Huseyin Kadioglu, Huseyin Kazim Bektasoglu, Zuhal Gucin, Seyma Yildiz, Mehmet Guzel, Ezgi Basak Erdogan, Serap Yucel, Yeliz Emine Ersoy
Objective To investigate the role of positron emission tomography (PET) and magnetic resonance imaging (MRI) in evaluating the feasibility of skin-sparing mastectomy in patients with locally-advanced breast cancer (LABC) who will undergo neoadjuvant chemotherapy (NAC) by evaluating the sensitivity and specificity of PET and MRI compared with skin biopsy results before and after NAC treatment. Methods Patients with LABC who were treated with NAC between November 2013 and November 2015 were included in this study...
January 1, 2018: Journal of International Medical Research
https://www.readbyqxmd.com/read/29327056/neoadjuvant-systemic-therapy-for-breast-cancer-searching-for-more-effectively-curative-therapies
#6
Joseph A Sparano
No abstract text is available yet for this article.
January 11, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29326029/neoadjuvant-treatment-with-trastuzumab-and-pertuzumab-plus-palbociclib-and-fulvestrant-in-her2-positive-er-positive-breast-cancer-na-pher2-an-exploratory-open-label-phase-2-study
#7
Luca Gianni, Giancarlo Bisagni, Marco Colleoni, Lucia Del Mastro, Claudio Zamagni, Mauro Mansutti, Milvia Zambetti, Antonio Frassoldati, Raffaella De Fato, Pinuccia Valagussa, Giuseppe Viale
BACKGROUND: In the neoadjuvant setting, blockade of HER2 plus use of an aromatase inhibitor in patients with HER2-positive and oestrogen receptor (ER)-positive breast cancer leads to a pathological complete response in 21% of patients. Convergence of HER2 and ER signals on RB1 suggests that a combined pharmacological intervention directed to these targets could be synergistic. To test this approach, we combined palbociclib to block RB1, fulvestrant to block ER, and trastuzumab with pertuzumab to block HER2 in patients with HER2-positive, ER-positive breast cancer...
January 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29322067/combining-multiparametric-mri-with-receptor-information-to-optimize-prediction-of-pathologic-response-to-neoadjuvant-therapy-in-breast-cancer-preliminary-results
#8
Hakmook Kang, Allison Hainline, Lori R Arlinghaus, Stephanie Elderidge, Xia Li, Vandana G Abramson, Anuradha Bapsi Chakravarthy, Richard G Abramson, Brian Bingham, Kareem Fakhoury, Thomas E Yankeelov
Pathologic complete response following neoadjuvant therapy (NAT) is used as a short-term surrogate marker of eventual outcome in patients with breast cancer. Analyzing voxel-level heterogeneity in MRI-derived parametric maps, obtained before and after the first cycle of NAT ([Formula: see text]), in conjunction with receptor status, may improve the predictive accuracy of tumor response to NAT. Toward that end, we incorporated two MRI-derived parameters, the apparent diffusion coefficient and efflux rate constant, with receptor status in a logistic ridge-regression model...
January 2018: Journal of Medical Imaging
https://www.readbyqxmd.com/read/29298865/neoadjuvant-oncolytic-virotherapy-before-surgery-sensitizes-triple-negative-breast-cancer-to-immune-checkpoint-therapy
#9
Marie-Claude Bourgeois-Daigneault, Dominic Guy Roy, Amelia Sadie Aitken, Nader El Sayes, Nikolas Tim Martin, Oliver Varette, Theresa Falls, Lauren Elizabeth St-Germain, Adrian Pelin, Brian Dennis Lichty, David Francis Stojdl, Guy Ungerechts, Jean-Simon Diallo, John Cameron Bell
Triple-negative breast cancer (TNBC) is an aggressive disease for which treatment options are limited and associated with severe toxicities. Immunotherapeutic approaches like immune checkpoint inhibitors (ICIs) are a potential strategy, but clinical trials have demonstrated limited success in this patient cohort. Clinical studies using ICIs have revealed that patients with preexisting anticancer immunity are the most responsive. Given that oncolytic viruses (OVs) induce antitumor immunity, we investigated their use as an ICI-sensitizing approach...
January 3, 2018: Science Translational Medicine
https://www.readbyqxmd.com/read/29298305/response-monitoring-of-breast-cancer-patients-receiving-neoadjuvant-chemotherapy-using-quantitative-ultrasound-texture-and-molecular-features
#10
Lakshmanan Sannachi, Mehrdad Gangeh, Hadi Tadayyon, Ali Sadeghi-Naini, Sonal Gandhi, Frances C Wright, Elzbieta Slodkowska, Belinda Curpen, William Tran, Gregory J Czarnota
BACKGROUND: Pathological response of breast cancer to chemotherapy is a prognostic indicator for long-term disease free and overall survival. Responses of locally advanced breast cancer in the neoadjuvant chemotherapy (NAC) settings are often variable, and the prediction of response is imperfect. The purpose of this study was to detect primary tumor responses early after the start of neoadjuvant chemotherapy using quantitative ultrasound (QUS), textural analysis and molecular features in patients with locally advanced breast cancer...
2018: PloS One
https://www.readbyqxmd.com/read/29296631/features-of-mri-stromal-enhancement-with-neoadjuvant-chemotherapy-a-subgroup-analysis-of-the-acrin-6657-i-spy-trial
#11
Adam Olshen, Denise Wolf, Ella F Jones, David Newitt, Laura van 't Veer, Christina Yau, Laura Esserman, Julia D Wulfkuhle, Rosa I Gallagher, Lisa Singer, Emanuel F Petricoin, Nola Hylton, Catherine C Park
Although the role of cancer-activated stroma in malignant progression has been well investigated, the influence of an activated stroma in therapy response is not well understood. Using retrospective pilot cohorts, we previously observed that MRI detected stromal contrast enhancement was associated with proximity to the tumor and was predictive for relapse-free survival in patients with breast cancer receiving neoadjuvant chemotherapy. Here, to evaluate the association of stromal contrast enhancement to therapy, we applied an advanced tissue mapping technique to evaluate stromal enhancement patterns within 71 patients enrolled in the I-SPY 1 neoadjuvant breast cancer trial...
January 2018: Journal of Medical Imaging
https://www.readbyqxmd.com/read/29291168/metronomic-chemotherapy-for-non-metastatic-triple-negative-breast-cancer-selection-is-the-key
#12
REVIEW
Connie Rabanal, Rossana Ruiz, Silvia Neciosup, Henry Gomez
Triple negative breast cancer (TNBC) accounts for 15%-20% of all breast cancer, and is still defined as what it is not. Currently, TNBC is the only type of breast cancer for which there are no approved targeted therapies and maximum tolerated dose chemotherapy with taxanes and anthracycline-containing regimens is still the standard of care in both the neoadjuvant and adjuvant settings. In the last years, metronomic chemotherapy (MC) is being explored as an alternative to improve outcomes in TNBC. In the neoadjuvant setting, purely metronomic and hybrid approaches have been developed with the objective of increasing complete pathologic response (pCR) and prolonging disease free survival...
December 10, 2017: World Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29290565/serum-vitamin-d-levels-affect-pathologic-complete-response-in-patients-undergoing-neoadjuvant-systemic-therapy-for-operable-breast-cancer
#13
Akiko Chiba, Rachna Raman, Alexandra Thomas, Pierre-Jean Lamy, Marie Viala, Stephane Pouderoux, Sarah L Mott, Mary C Schroeder, Simon Thezenas, William Jacot
INTRODUCTION: There has been increasing interest in the potential benefit of vitamin D in improving breast cancer outcome. Preclinical studies suggest that vitamin D enhances chemotherapy-induced cell death. We investigated the impact of serum vitamin D levels during neoadjuvant chemotherapy (NAC) on the rates of achieving pathologic complete response (pCR) after breast cancer NAC. PATIENTS AND METHODS: Patients from 1 of 2 Iowa registries who had serum vitamin D level measured before or during NAC were included...
December 11, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29289334/does-preoperative-axillary-staging-lead-to-overtreatment-of-women-with-screen-detected-breast-cancer
#14
M G Wallis, F Kilburn-Toppin, S Taylor-Phillips
AIM: To determine the impact of preoperative axillary ultrasound staging in a screen-detected breast cancer population. MATERIALS AND METHODS: Ultrasound and needle biopsy staging results alongside reference standard sentinel lymph node biopsy and axillary lymph node dissection were extracted retrospectively from the unit's computer records between 1 April 2008 and 31 March 2015. Axillary staging was compared with final histopathology and treatment. RESULTS: Of the 215,661 screening examinations performed, 780 invasive cancers were diagnosed, which had preoperative axillary staging data, of which 162 (20...
December 27, 2017: Clinical Radiology
https://www.readbyqxmd.com/read/29285378/phase-ii-study-of-neoadjuvant-anthracycline-combined-with-nanoparticle-albumin-bound-paclitaxel-for-human-epidermal-growth-factor-receptor-2-negative-breast-cancer
#15
Emi Ishigami, Masahiro Sakakibara, Junta Sakakibara, Toshiaki Iwase, Shoko Hayama, Takahito Masuda, Ayako Nakagawa, Takeshi Nagashima, Takafumi Sangai, Hiroshi Fujimoto, Masayuki Otsuka
Neoadjuvant chemotherapy (NAC) with anthracyclines followed by taxane chemotherapy has become the standard treatment for patients with locally advanced, operable breast cancer. Recently, the efficacy of nanoparticle albumin-bound paclitaxel (nab-PTX) for metastatic breast cancer was reported. However, there are still few studies of a neoadjuvant regimen including nab-PTX. Thus, the present phase II study evaluated the efficacy and safety of 5-fluorouracil, epirubicin and cyclophosphamide (FEC regimen) followed by nab-PTX as neoadjuvant treatment for operable human epidermal growth factor receptor 2 (HER2)-negative breast cancer...
December 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29280449/postmastectomy-radiation-in-breast-cancer-patients-with-pathologically-positive-lymph-nodes-after-neoadjuvant-chemotherapy-usage-rates-and-survival-trends
#16
Nisha Ohri, Erin Moshier, Alice Ho, Sheryl Green, Ryan Rhome, Madhu Mazumdar, Simon Powell, Chiaojung Jillian Tsai
PURPOSE: To analyze postmastectomy radiation therapy (PMRT) usage and its association with overall survival (OS) in breast cancer patients with pathologically positive lymph nodes after neoadjuvant chemotherapy (NAC). METHODS AND MATERIALS: Using the National Cancer Database, we identified women with nonmetastatic breast cancer diagnosed from 2004 to 2013 who had received NAC and undergone mastectomy with macroscopic pathologically positive lymph nodes. Joinpoint regression models were used to assess temporal trends in annual PMRT usage...
November 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29280043/cardiac-biomarkers-for-early-detection-and-prediction-of-trastuzumab-and-or-lapatinib-induced-cardiotoxicity-in-patients-with-her2-positive-early-stage-breast-cancer-a-neoaltto-sub-study-big-1-06
#17
Noam Ponde, Ian Bradbury, Matteo Lambertini, Michael Ewer, Christine Campbell, Helene Ameels, Dimitrios Zardavas, Serena Di Cosimo, José Baselga, Jens Huober, Miguel Izquierdo, Debora Fumagalli, Ivana Bozovic-Spasojevic, Marion Maetens, Nadia Harbeck, Lajos Pusztai, Michael Berghorn, Young-Hyuck Im, Manuel Ruiz Borrego, Dar-Ren Chen, Richard Rodeheffer, Martine Piccart, Thomas Suter, Evandro de Azambuja
BACKGROUND: Biomarkers of cardiac damages, such as troponin T (TnT) and the amino-terminal fragment of brain natriuretic peptide (NT-proBNP), may be useful as early predictors of cardiac dysfunction. The role of these biomarkers in patients receiving lapatinib and/or trastuzumab before anthracyclines is unknown. This study explores TnT and NT-proBNP as predictors of early cardiac toxicity in neoadjuvant breast cancer patients. METHODS: This sub-study of the NEOALTTO trial tested if changes in the levels of TnT and NT-proBNP occurred after 2 weeks of anti-HER2 therapy (lapatinib, trastuzumab or their combination) alone and/or after 18 weeks of anti-HER2 therapy plus weekly paclitaxel...
December 27, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29275435/homologous-recombination-deficiency-hrd-status-predicts-response-to-standard-neoadjuvant-chemotherapy-in-patients-with-triple-negative-or-brca1-2-mutation-associated-breast-cancer
#18
Melinda L Telli, Jessica Hellyer, William Audeh, Kristin C Jensen, Shikha Bose, Kirsten M Timms, Alexander Gutin, Victor Abkevich, Rebecca N Peterson, Chris Neff, Elisha Hughes, Zaina Sangale, Joshua Jones, Anne-Renee Hartman, Pei-Jen Chang, Shaveta Vinayak, Richard Wenstrup, James M Ford
PURPOSE: Defects in the homologous recombination (HR) DNA repair pathway sensitize tumors to therapeutics that target this pathway. A significant proportion of triple-negative breast cancers (TNBC) carry HR defects. The HRD assay is highly associated with sensitivity to neoadjuvant platinum-based chemotherapy in TNBC. Standard chemotherapy consists of some combination of an anthracycline, cyclophosphamide, and taxane. This study assesses the association of HR deficiency status with response to standard neoadjuvant chemotherapy in TNBC or BRCA1/2 mutation-associated breast cancer...
December 23, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29259013/the-carma3-bcl10-malt1-signalosome-drives-nf-%C3%AE%C2%BAb-activation-and-promotes-aggressiveness-in-angiotensin-ii-receptor-positive-breast-cancer
#19
Prasanna Ekambaram, Jia-Ying Lloyd Lee, Nathaniel E Hubel, Dong Hu, Saigopalakrishna Yerneni, Phil G Campbell, Netanya Pollock, Linda R Klei, Vincent J Concel, Phillip C Delekta, Arul M Chinnaiyan, Scott A Tomlins, Daniel R Rhodes, Nolan Priedigkeit, Adrian V Lee, Steffi Oesterreich, Linda McAllister-Lucas, Peter C Lucas
The angiotensin II receptor AGTR1, which mediates vasoconstrictive and inflammatory signaling in vascular disease, is overexpressed aberrantly in some breast cancers. In this study, we established the significance of an AGTR1-responsive NF-κB signaling pathway in this breast cancer subset. We documented that AGTR1 overexpression occurred in the luminal A and B subtypes of breast cancer, was mutually exclusive of HER2 expression, and correlated with aggressive features that include increased lymph node metastasis, reduced responsiveness to neoadjuvant therapy, and reduced overall survival...
December 19, 2017: Cancer Research
https://www.readbyqxmd.com/read/29250202/asco-2017-highlights-in-breast-cancer
#20
REVIEW
Rupert Bartsch, Elisabeth Bergen
At the 2017 ASCO Annual Meeting, several pertinent studies in the field of breast cancer were presented and some are deemed as being potentially practice changing. BrighTNess was the first phase III study to investigate the addition of carboplatin to standard neoadjuvant chemotherapy in triple-negative breast cancer; while toxicity was increased in the experimental group, a significantly higher pathologic complete remission (pCR) rate was observed as well suggesting that adding carboplatin to neoadjuvant anthracycline, cyclophosphamide and taxane-containing regimens is efficacious in otherwise healthy patients...
2017: Memo
keyword
keyword
74676
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"